S&P 500   3,960.38 (+0.67%)
DOW   33,731.55 (+0.40%)
QQQ   283.93 (+1.21%)
AAPL   142.79 (+1.31%)
MSFT   247.41 (+1.24%)
META   115.64 (+1.50%)
GOOGL   94.22 (-0.76%)
AMZN   90.49 (+2.29%)
TSLA   173.92 (-0.07%)
NVDA   170.75 (+5.92%)
NIO   13.40 (+6.52%)
BABA   93.88 (+6.28%)
AMD   70.20 (+0.09%)
T   19.10 (-1.04%)
MU   55.16 (+2.49%)
CGC   3.00 (-7.41%)
F   13.13 (+0.23%)
GE   83.24 (-2.07%)
DIS   92.37 (+0.24%)
AMC   6.12 (+1.16%)
PYPL   74.53 (+0.15%)
PFE   51.49 (+2.49%)
NFLX   309.76 (+0.43%)
S&P 500   3,960.38 (+0.67%)
DOW   33,731.55 (+0.40%)
QQQ   283.93 (+1.21%)
AAPL   142.79 (+1.31%)
MSFT   247.41 (+1.24%)
META   115.64 (+1.50%)
GOOGL   94.22 (-0.76%)
AMZN   90.49 (+2.29%)
TSLA   173.92 (-0.07%)
NVDA   170.75 (+5.92%)
NIO   13.40 (+6.52%)
BABA   93.88 (+6.28%)
AMD   70.20 (+0.09%)
T   19.10 (-1.04%)
MU   55.16 (+2.49%)
CGC   3.00 (-7.41%)
F   13.13 (+0.23%)
GE   83.24 (-2.07%)
DIS   92.37 (+0.24%)
AMC   6.12 (+1.16%)
PYPL   74.53 (+0.15%)
PFE   51.49 (+2.49%)
NFLX   309.76 (+0.43%)
S&P 500   3,960.38 (+0.67%)
DOW   33,731.55 (+0.40%)
QQQ   283.93 (+1.21%)
AAPL   142.79 (+1.31%)
MSFT   247.41 (+1.24%)
META   115.64 (+1.50%)
GOOGL   94.22 (-0.76%)
AMZN   90.49 (+2.29%)
TSLA   173.92 (-0.07%)
NVDA   170.75 (+5.92%)
NIO   13.40 (+6.52%)
BABA   93.88 (+6.28%)
AMD   70.20 (+0.09%)
T   19.10 (-1.04%)
MU   55.16 (+2.49%)
CGC   3.00 (-7.41%)
F   13.13 (+0.23%)
GE   83.24 (-2.07%)
DIS   92.37 (+0.24%)
AMC   6.12 (+1.16%)
PYPL   74.53 (+0.15%)
PFE   51.49 (+2.49%)
NFLX   309.76 (+0.43%)
S&P 500   3,960.38 (+0.67%)
DOW   33,731.55 (+0.40%)
QQQ   283.93 (+1.21%)
AAPL   142.79 (+1.31%)
MSFT   247.41 (+1.24%)
META   115.64 (+1.50%)
GOOGL   94.22 (-0.76%)
AMZN   90.49 (+2.29%)
TSLA   173.92 (-0.07%)
NVDA   170.75 (+5.92%)
NIO   13.40 (+6.52%)
BABA   93.88 (+6.28%)
AMD   70.20 (+0.09%)
T   19.10 (-1.04%)
MU   55.16 (+2.49%)
CGC   3.00 (-7.41%)
F   13.13 (+0.23%)
GE   83.24 (-2.07%)
DIS   92.37 (+0.24%)
AMC   6.12 (+1.16%)
PYPL   74.53 (+0.15%)
PFE   51.49 (+2.49%)
NFLX   309.76 (+0.43%)
NYSE:TMO

Thermo Fisher Scientific - TMO Price Target & Analyst Ratings

$567.95
+9.81 (+1.76%)
(As of 12/8/2022 03:27 PM ET)
Add
Compare
Today's Range
$557.00
$569.01
50-Day Range
$484.71
$564.56
52-Week Range
$475.77
$672.34
Volume
47,038 shs
Average Volume
1.43 million shs
Market Capitalization
$222.75 billion
P/E Ratio
31.93
Dividend Yield
0.22%
Price Target
$623.11

Thermo Fisher Scientific Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 10 Analyst Ratings

Consensus Analyst Price Target

$623.11
9.71% Upside
High Prediction$718.00
Average Prediction$623.11
Low Prediction$525.00
TypeCurrent
12/8/21 to 12/8/22
1 Month Ago
11/8/21 to 11/8/22
3 Months Ago
9/9/21 to 9/9/22
1 Year Ago
12/8/20 to 12/8/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
7 Buy rating(s)
6 Buy rating(s)
11 Buy rating(s)
15 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$623.11$619.00$662.07$627.82
Predicted Upside9.71% Upside17.67% Upside11.78% Upside11.83% Upside
Get Thermo Fisher Scientific Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TMO and its competitors with MarketBeat's FREE daily newsletter.


TMO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TMO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Thermo Fisher Scientific Stock vs. The Competition

TypeThermo Fisher ScientificMedical CompaniesS&P 500
Consensus Rating Score
2.60
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside9.77% Upside597.68% Upside14.65% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
1016
83.01%
Underperform Votes
208
16.99%
Avg. Outperform Votes
163
66.26%
Avg. Underperform Votes
83
33.74%
Avg. Outperform Votes
853
68.13%
Avg. Underperform Votes
399
31.87%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/6/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$661.00+20.07%
11/29/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$575.00 ➝ $570.00+5.55%
10/27/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$620.00+23.98%
10/27/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$678.00 ➝ $613.00+21.87%
10/27/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$711.00 ➝ $696.00+38.37%
10/27/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$715.00 ➝ $650.00+29.22%
10/27/2022Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
10/27/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$590.00 ➝ $555.00+10.34%
4/25/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeEqual Weight ➝ Underweight$605.00 ➝ $525.00-6.46%
2/3/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Sung Ji Nam
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$718.00+20.57%
10/14/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$655.00 ➝ $696.00+20.55%
9/23/2021The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeBuy ➝ Conviction-Buy
9/21/2021UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$595.00 ➝ $670.00+13.52%
9/20/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Brandon Couillard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$540.00-9.16%
9/20/2021KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Paul Knight
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight$555.00 ➝ $710.00+18.97%
9/20/2021JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$600.00 ➝ $700.00+17.29%
8/4/2021Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetAverage ➝ Buy$530.00 ➝ $600.00+11.73%
4/16/2021Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$525.00 ➝ $540.00+9.65%
2/2/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$530.00 ➝ $600.00+16.40%
12/16/2020Smith Barney Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
10/27/2020Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Stephen Unger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$477.00 ➝ $539.00+11.73%
9/30/2020Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$494.00+13.74%
9/11/2020Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$460.00 ➝ $480.00+12.15%
(Data available from 12/8/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












TMO Price Target - Frequently Asked Questions

What is Thermo Fisher Scientific's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for Thermo Fisher Scientific stock is Moderate Buy based on the current 1 sell rating, 2 hold ratings and 7 buy ratings for TMO. The average twelve-month price prediction for Thermo Fisher Scientific is $623.11 with a high price target of $718.00 and a low price target of $525.00. Learn more on TMO's analyst rating history.

Do Wall Street analysts like Thermo Fisher Scientific more than its competitors?

Analysts like Thermo Fisher Scientific less than other Medical companies. The consensus rating for Thermo Fisher Scientific is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how TMO compares to other companies.

Do MarketBeat users like Thermo Fisher Scientific more than its competitors?

MarketBeat users like Thermo Fisher Scientific more than other Medical companies. 83.01% of MarketBeat users gave Thermo Fisher Scientific an outperform vote while medical companies recieve an average of 66.26% outperform votes by MarketBeat users.

Is Thermo Fisher Scientific being downgraded by Wall Street analysts?

Over the previous 90 days, Thermo Fisher Scientific's stock had 1 downgrade by analysts.

Does Thermo Fisher Scientific's stock price have much upside?

According to analysts, Thermo Fisher Scientific's stock has a predicted upside of 16.93% based on their 12-month price targets.

What analysts cover Thermo Fisher Scientific?

Thermo Fisher Scientific has been rated by Barclays, Benchmark, Citigroup, Credit Suisse Group, Morgan Stanley, Robert W. Baird, Royal Bank of Canada, and SVB Leerink in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:TMO) was last updated on 12/8/2022 by MarketBeat.com Staff